Latest Insights by martyn
Llusern bags a hat-trick at ICS 2026.
Llusern is pleased to announce that three abstracts will be presented at the International Continence Society congress in Maastricht, 6-9…
Two abstracts published in The Journal of Urology.
Llusern Scientific was pleased that two abstracts assessing the Lodestar UTI testing panel in clinical settings were published in the…
Llusern announces changes to Exec team and new NED
21st April 2026 Llusern Scientific Announces Changes To Executive Management Team And New NED Appointments made to advance the commercial…
Introducing Lodestar UTI into your clinic. Download this handy guide today.
This guide to introducing Lodestar UTI has been written to answer questions from private – and NHS – clinics who…
Llusern to attend WHX Dubai 9-12 February 2026
Next month Llusern Scientific will be at WHX 2026 as part of the Welsh Government trade mission travelling to the…
Lodestar UTI to be presented at two major urology congresses
Llusern Scientific is delighted to announce that Lodestar DX will be present at two leading urology conferences in 2026. The…
Mobile community UTI testing arrives in Glasgow in 2026
“NHS Greater Glasgow and Clyde is seeing the launch of a new community diagnostic vehicle, in a move designed to…
Quick and accurate UTI diagnostics make for better clinical decisions
A study undertaken at the Royal Berkshire Hospital in Reading in the last few months looked at how Lodestar performed against lab…
New webinar: A real-world performance study of the Lodestar UTI testing system
Following the success of our first Lodestar DX webinar we are pleased to share that we will be hosting another…
New study data demonstrates Lodestar more accurate than lab culture
In an independent study undertaken at the Royal Berkshire Hospital, in September to October 2025, Lodestar was tested against the…
Barclays Entrepreneur of the Year and Beyond Biotech podcast
On Thursday 6 November Llusern CEO Dr Emma Hayhurst and Managing Director Martyn Lewis attended the Barclays Entrepreneur of the…
New antibiogram data shows Lodestar covers 96% of UTI pathogens
New NHS study data shows that 96% of UTIs are caused by only six pathogens, all of which are detected…
Start a conversation with Llusern
Llusern is developing treatment-directing diagnostics for high-volume healthcare challenges, starting with rapid molecular UTI testing. To learn more about the company, the product and the opportunity ahead, speak to the Llusern team.